PHARMACEUTICAL 2016

Jazz Pharmaceuticals plc
Rank 10 of 295



TOP RATED 2016

RealRate

PHARMACEUTICAL 2016

Jazz Pharmaceuticals plc
Rank 10 of 295

Jazz Pharmaceuticals

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 116% points.The greatest weakness of Jazz Pharmaceuticals plc is the variable Assets, Current, reducing the Economic Capital Ratio by 5.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 436%, being 173% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	1,257,667
Cost of Goods Sold	0
Intangible Assets	1,842,745
Liabilities, Current	226,642
Liabilities, Non-Current	0
Other Assets	173,679
Other Compr. Net Income	-145,374
Other Expenses	338,610
Other Liabilities	0
Other Net Income	-72,287
Other Revenues	1,324,803
Property and Equipment	85,572
Research and Development	135,253
Selling, General and Administrative Expense	449,119

Output Variable	Value in 1000 USD
Assets	3,359,663
Liabilities	226,642
Expenses	922,982
Revenues	1,324,803
Stockholders Equity	3,133,021
Net Income	329,534
Comprehensive Net Income	256,847
BaseVar	3,025,876
ECR before LimitedLiability	395%
Economic Capital Ratio	436%